FDA MARKETING APPROVAL FOR MARIJUANA ASSAY RANCHO CUCAMONGA, Calif., June 9 /PRNewswire/ -- U.S. Drug Testing Inc. (Pacific: USD.P) announced today that it has received notice from the Food And Drug Administration (FDA) that its 510(k) application, submitted on Feb. 22, 1994, has been determined to be substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments. The application submitted is for the assay which detects cannabinoid (THC) in urine utilizing the Flow Immunosensor Technology. The company had previously received FDA marketing approvals for the Flow Immunoassay System, Model 9000; for the assay which detects cocaine and its metabolite benzoylecgonine; for the assay which detects opiates, including heroin, morphine and amphetamines; and for the assay which detects phencyclidine (PCP). The notification from the FDA permits the company to begin marketing the device subject to the general control provisions of the Medical Device Amendments Act including requirements for registration, listing of the device, good manufacturing practice, and labeling. The Flow Immunosensor Technology provides a more sensitive method for testing for drugs of abuse while significantly decreasing the assay time and cost. This technology, developed by scientists at the Naval Research Laboratory, was licensed to the company in January 1992 from the United States government through the Technology Transfer Act. A subsequent one year Cooperative Research and Development Agreement was signed in April 1992, and was extended until June 1994. U.S. Drug Testing is a 67 percent owned subsidiary of U.S. Alcohol Testing of America Inc. (AMEX: AAA) and is engaged in the research and development of devices which detect drugs of abuse from urine and saliva samples. -0- 6/9/94 /CONTACT: Gary S. Wolff, 909-466-8378/ (USD.P AAA) CO: U.S. Drug Testing Inc.; U.S. Alcohol Testing of America ST: California IN: SU: Transmitted: 94-06-09 20:01:59 EDT